Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Webb

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Inflammation|June 1, 1993
Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory responseD E Griswold, E F Webb, J Breton, et al.
Inflammation|December 1, 1989
Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493D E Griswold, S Hoffstein, P J Marshall, et al.
International Journal of Immunopharmacology|April 1, 1993
Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progressionA M Badger, B A Swift, E F Webb, et al.
International Journal of Immunopharmacology|October 1, 1994
Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responsesM P Reddy, E F Webb, D Cassatt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formationL A Marshall, J D Winkler, D E Griswold, et al.
Biochemical Pharmacology|August 4, 1991
Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivoD E Griswold, P J Marshall, J C Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 10, 1998
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivoD E Griswold, E F Webb, A M Badger, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2001
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activityJ L Adams, J C Boehm, T F Gallagher, et al.
Biochemical Pharmacology|October 15, 1987
SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acidD E Griswold, P J Marshall, E F Webb, et al.
Biochemical Pharmacology|August 4, 1991
Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acidP J Marshall, D E Griswold, J Breton, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Inflammation|June 1, 1993
Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory responseD E Griswold, E F Webb, J Breton, et al.
Inflammation|December 1, 1989
Inhibition of inflammatory cell infiltration by bicyclic imidazoles, SK&F 86002 and SK&F 104493D E Griswold, S Hoffstein, P J Marshall, et al.
International Journal of Immunopharmacology|April 1, 1993
Beneficial effects of SK&F 105685 in rat adjuvant arthritis: prophylactic and therapeutic effects on disease parameter progressionA M Badger, B A Swift, E F Webb, et al.
International Journal of Immunopharmacology|October 1, 1994
Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responsesM P Reddy, E F Webb, D Cassatt, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Effects of scalaradial, a type II phospholipase A2 inhibitor, on human neutrophil arachidonic acid mobilization and lipid mediator formationL A Marshall, J D Winkler, D E Griswold, et al.
Biochemical Pharmacology|August 4, 1991
Pharmacology of the pyrroloimidazole, SK&F 105809--II. Antiinflammatory activity and inhibition of mediator production in vivoD E Griswold, P J Marshall, J C Lee, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 10, 1998
SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivoD E Griswold, E F Webb, A M Badger, et al.
Bioorganic & Medicinal Chemistry Letters|October 13, 2001
Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activityJ L Adams, J C Boehm, T F Gallagher, et al.
Biochemical Pharmacology|October 15, 1987
SK&F 86002: a structurally novel anti-inflammatory agent that inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acidD E Griswold, P J Marshall, E F Webb, et al.
Biochemical Pharmacology|August 4, 1991
Pharmacology of the pyrroloimidazole, SK&F 105809--I. Inhibition of inflammatory cytokine production and of 5-lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acidP J Marshall, D E Griswold, J Breton, et al.
Pageof 4